Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy approach in AML ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

ICT01 selectively activates circulating γ9δ2 T cells that leads to migration of γ9δ2 T cells out of the circulation and into target tissue (e.g., tumors or infection site), ...

ImCheck Therapeutics SAS. ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022. Continued positive safety data across a ...

Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trial show strong safety profile and encouraging clinical activity for ICT01 monotherapy in relapsed/refractory ...

Two clinical trials are underway to test ICT01: Eviction is testing the drug alone and in combination with Merck's Keytruda. Eviction-2 is testing the drug with an IL-2 inhibitor.

ImCheck Reports High Remission Rates in AML Patientswith ICT01 Combination Therapy at ASCO 2025 ICT01 in combination with azacitidine and venetoclax (Aza-Ven) achieves unprecedented high remission ...

ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023Interim data from ...

ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...